Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-06-27
2006-06-27
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S136100, C424S143100, C424S144100, C424S147100, C424S150100, C424S155100, C530S387300, C530S388100, C530S388200, C530S388400, C530S391100, C530S391700
Reexamination Certificate
active
07067128
ABSTRACT:
Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.
REFERENCES:
patent: 5005588 (1991-04-01), Rubin
patent: 5258372 (1993-11-01), Levy
patent: 5332567 (1994-07-01), Goldenberg
patent: 6468530 (2002-10-01), Goldenberg
patent: 2093866 (1993-10-01), None
patent: 689 07 430 (1989-10-01), None
patent: 0 118 915 (1984-09-01), None
patent: 0 217 404 (1987-04-01), None
patent: 0 256 714 (1988-02-01), None
patent: 89303080.9 (1989-03-01), None
patent: 0 336 631 (1993-07-01), None
patent: 0 569 141 (1993-11-01), None
patent: WO 92/08802 (1992-05-01), None
patent: WO 93/02105 (1993-02-01), None
patent: WO 93/19094 (1993-09-01), None
patent: WO 93/25700 (1993-12-01), None
Bray et al., “Malaria Chemotherapy: Resistance to Quinoline Containing Drugs in Plasmodium Falciparum,” FEMS Microbiol. Lett. (1993) 113:1-8.
Calabresi, “Drug Resistance: Lonidamine,” PPO Updates (Jun. 1994), 8(6):1-15.
Chen et al., “Internal Duplication and Homology with Bacterial Transport Proteins in the mdr1 (P-Glycoprotein) Gene from Multidrug-Resistant Human Cells,” Cell (Nov. 7, 1986) 47:318-389.
Childs et al., “The MDR Superfamily of Genes and its Biological Implications,” Important Advances in Oncology, De Vita et al. (Eds.) pp. 21-36 (J.P. Lippincott 1994).
Dalton et al., “Immunohistochemical Detection and Quantitation of P-Glycoprotein in Multiple Drug-Resistance Human Myeloma Cells: Association With Level of Drug Resistance and Drug Accumulation,” Blood (Feb. 15, 1989) 73:747-752.
Deyoung, “Biotech Companies and Drug Firms Take Steps to Combat Drug-Resistant Bacteria,” Genetic Engineering News (Jul. 14, 1994) 14:1, 14.
Doige et al., “ATP-Dependent Transport Systems in Bacterial and Humans: Relevance to Cystic Fibrosis and Multidrug Resistance,” Annu. Rev. Microbiol. (1993), 47:291-319.
Durrant et al., “Sensitivity of Newly Established Colorectal Cell Lines to Cytotoxic Drugs and Monoclonal Antibody Drug Conjugates,” Br. J. Cancer (1987), 56:772-726.
Sheldon et al., “Sensitivity of Multidrug Resistant KB-C1 Cells to an Antibody-Dextran-Adriamycin Conjugate,” Anticancer Research (1989), 9:637-642.
Tong et al., “Elimination of Chemoresistant Multiple Myaloma Clonogenic Colony-forming Cells by Combined Treatment with a Plasma Cell-reactive Monoclonal Antibody and a P-Glycoprotein-reactive Monoclonal Antibody,” Cancer Res. (Sep. 1, 1989), 49:4829-4834.
Van Duk et al., Bispecific Antibodies Reactive with the Multidrug-Resistance-Related Glycoprotein and CD3 Induce Lysis of Multidrug-Resistant Tumor Cells, Int. J. Cancer (1989) 44:738-743.
Volm et al., “Detection of Multidrug Resistant Phenotype in Human Tumorus by Monoclonal Antibodies and the Streptavidin-Biotinylated Phycoerythrin Complex Methods,” Eur. J. Cancer Clin. Oncol. (1989) 23(4):743-749.
Fitzgerald et al., “A Monoclonal Antibody-Pseudomonas Toxin Conjugate That Specifically Kills Multi-drug Resistant Cells”,Proc. Natl. Acad. Sci. USA, vol. 84, pp. 4288-4292, Jun. 1987, Medical Sciences.
Efferth et al., “Antibody-Directed Therapy of Multidrug-Resistant Tumor Cells,” Med. Oncol. & Tumor Pharmacother. (1992), 9(1)11-19.
Endicott et al., “The Biochemistry of P-Glycoprotein-Mediated Multidrug Resistance,” Annu. Rev. Biochem. (1989) 58:137-171.
Fitzgerald et al., A Monoclonal Antibody-Pseudomonas Toxin Conjugate That Specifically Kills Multidrug-Resistant Cells.
Georges et al., “Modulation of ATP and Drug Binding By Monoclonal Antibodies Against P-Glycoprotein,” J. Cell Physiol. (1991), 148:479-484.
Goldstein et al., “Expression of a Multidrug Resistance Gene in Human Cancers,” J. Natl. Cancer Inst. (Jan. 18, 1989), 81:116-124.
Grinius et al., “A Staphylococcal Multidrug Resistance Gene Product is a Member of a New Protein Family,” Plasmid (1992), 27:119-129.
Hamada et al., “Functional Role for the 170-to 180-kDa Glycoprotein Specific to Drug-Resistant Tumor Cells As Revealed by Monoclonal Antibodies,” Proc. Natl. Acad. Sci. USA (Oct 1986) 83:7785-7789.
Iwahashi et al., “Specific Targeting and Killing Activities of Anti-P-Glycoprotein Monoclonal Antibody MRK 16 Directed Against Intrinsically Multidrug-Resistant Human Colorectal Carcinoma Cell Lines in the Nude Mouse Model,” Cancer Research (Nov. 15, 1993), 53:5475-5482.
Neyfakh et al., “Efflux-Mediated Multidrug Resistance inBacillus subtilis: Similarities and Dissimilarities With the Mammalian System,” Proc. Natl. Acad. Sci. USA (Jun. 1991), 88:4781-4785.
Noonan et al., “Quantitative Analysis of MDR1 (multidrug resistance) Gene Expression in Human Tumors By Polymerase Chain Reaction,” Proc. Natl. Acad. Sci. USA (Sep. 1990), 87:7160-7164.
Pearson et al., “Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by in Vivo Administration of MRK-16 Monoclonal Antibody,” J. Natl. Cancer Inst. (1991) 83:1386-1391.
Rittmann-Grauer et al., “Reversal of Finca Alkaloid Resistance by Anti-Glycoprotein Monoclonal Antibody HYB-241 in a Human Tumor Xenograft,” Cancer Res. (Apr. 1, 1992), 52:1810-1816.
Sarkadi et al., “Interaction of Bioactive Hydrophobic Peptides With the Human Multidrug Transporter,” The FASEB Journal (Jul. 1994), 8:766:770.
Schneider et al., “P-Glycoprotein Expression in Treated and Untreated Human Breast Cancer,” Br. J. Cancer (1989), 60:815-818.
Bird & Bird, Solilcitors for the Defendeant, F. Hoffmann-LaRoche LTd. v. Immunomedics, Inc., In the High Court of Justice Chancery Division Patents Court, Statement of Reasons, HC-04-C-02335, Oct. 21, 2004.
Vossius & Partner, Official document from F. Hoffmann-La Roche AG/Immunomedics, Inc., May 19, 2004.
Vossius & Partner, Letter from Dr. Hans-Rainer Jaaenichen, re: F. Hoffmann-La Roche AG/Immunomedics, Inc., Dec. 10, 2004.
Bohmann & Loosen, EP Application 04776666.2, dated Mar. 14, 2006, replacement p. 5.
Hoffmann-Elitle, Translation of the Brief as submitted ot he Federal Patent Court by Vossius & Partner, dated Dec. 7, 2004.
Hoffmann-Eitle, Translation of the Response to the Federal Patents Court, Jan. 20, 2005.
Motoyoshi, et al., “Clinical Application of Partially Purified Human Urinary Colony-Stimulating Factor,” Immunobiol., vol. 172, pp. 205-212 (1986).
Bronchud, M.H., et al., “Phase I/II study of recombinant human granulocyte colony-stimulating factor in Patients receiving intensive chemotherapy for small cell lung cancer” Br.J.Cancer (1987), 56, pp. 809-813, The Macmillian Press Ltd., 1987.
Morstyn, G., et al., “Effect of Granulocyte Colony Stimulating Factor on Neutropenia Induced by Cytotoxic Chemotherapy,” The Lancet, Mar. 28, 1988, pp. 667-672.
Moore, A.S. Malcolm, et al., “Synergy of Interleukin 1 and Granulocyte Colony-Stimulating factor: In vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5 fluorouracil treatment of mice,” Proc. Natl. Acad. Sci., USA vol. 84, pp. 7134-7138, Oct. 1987 Cell Biology.
Welte, Karl, et al., “Recombinant Human Granulocyte Colony-Stimulating Factor,” J. Exp. Med. The Rockefeller University Press 0022-1007/87/04/0941/08, vol. 165 Apr. 1987 pp. 941-948.
Gillio, A. P., et al., “Effects of Recombinant Human Granulocyte-Colony Stimulating Factor on Hematopoietic Reconstitution After Autologous Bone Marrow Transplantation in Primates” Transplantation Proceedings, vol. XIX, No.
Chan Christina
Faegre & Benson LLP
Huynh Phuong
Immunomedics Inc.
LandOfFree
Polyspecific immunoconjugates and antibody composites for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyspecific immunoconjugates and antibody composites for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyspecific immunoconjugates and antibody composites for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3660217